Journal
PHYTOTHERAPY RESEARCH
Volume 27, Issue 12, Pages 1842-1848Publisher
WILEY
DOI: 10.1002/ptr.4941
Keywords
Epilobium sp; oenothein B; urolithins; prostate specific antigen; arginase; LNCaP
Categories
Funding
- Polish National Science Center [2011/01/D/NZ4/01261]
- European Regional Development Found
Ask authors/readers for more resources
Extracts from Epilobium sp. herbs have been traditionally used in the treatment of prostate-associated ailments. Our studies demonstrated that the extracts from Epilobium angustifolium, Epilobium parviflorum and Epilobium hirsutum herbs are potent prostate cancer cells (LNCaP) proliferation inhibitors with IC50 values around 35 mu g/ml. The tested extracts reduced prostate specific antigen (PSA) secretion (from 325.6 +/- 25.3 ng/ml to similar to 90 ng/ml) and inhibited arginase activity (from 65.2 +/- 1.1 mUnits of urea/mg of protein to similar to 40 mUnits of urea/mg protein). Selected constituents of extracts (oenothein B, quercetin-3-O-glucuronide, myricetin-3-O-rhamnoside) were proven to be active in relation to LNCaP cells. However, oenothein B was the strongest inhibitor of cells proliferation (IC50=7.8 +/- 0.8 M), PSA secretion (IC50=21.9 +/- 3.2 M) and arginase activity (IC50=19.2 +/- 2.0 M). Additionally, ellagitannins from E. hirustum extract were proven to be transformed by human gut microbiota into urolithins. Urolithin C showed the strongest activity in the inhibition of cell proliferation (IC50=35.2 +/- 3.7 M), PSA secretion (reduced PSA secretion to the level of 100.7 +/- 31.0 ng/ml) and arginase activity (reduced to the level of 27.9 +/- 3.3 mUnits of urea/mg of protein). Results of the work offer an explanation of the activity of Epilobium extracts and support the use of Epilobium preparations in the treatment of prostate diseases. Copyright (c) 2013 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available